ADMA Biologics Inc (NASDAQ:ADMA) Expected to Earn FY2019 Earnings of ($0.92) Per Share

ADMA Biologics Inc (NASDAQ:ADMA) – Stock analysts at Oppenheimer lowered their FY2019 earnings per share estimates for shares of ADMA Biologics in a report issued on Thursday, November 7th. Oppenheimer analyst L. Gershell now expects that the biotechnology company will earn ($0.92) per share for the year, down from their previous forecast of ($0.90). Oppenheimer also issued estimates for ADMA Biologics’ Q4 2019 earnings at ($0.18) EPS, FY2020 earnings at ($0.37) EPS, FY2022 earnings at $0.47 EPS and FY2023 earnings at $0.66 EPS.

Get ADMA Biologics alerts:

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The company had revenue of $7.22 million for the quarter, compared to analysts’ expectations of $5.71 million. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%.

Several other research firms have also recently issued reports on ADMA. Dawson James cut ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price target on the stock. in a report on Monday, August 12th. Maxim Group set a $12.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Monday, October 21st. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Finally, ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $10.20.

NASDAQ ADMA opened at $4.31 on Monday. The stock has a market capitalization of $304.89 million, a P/E ratio of -2.97 and a beta of 2.70. ADMA Biologics has a 1 year low of $2.08 and a 1 year high of $6.31. The business’s fifty day moving average is $4.59 and its two-hundred day moving average is $4.26. The company has a debt-to-equity ratio of 1.79, a quick ratio of 7.93 and a current ratio of 10.26.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC grew its holdings in shares of ADMA Biologics by 76.7% during the 2nd quarter. Perceptive Advisors LLC now owns 11,521,102 shares of the biotechnology company’s stock valued at $44,586,000 after acquiring an additional 5,000,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of ADMA Biologics by 47.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,448,253 shares of the biotechnology company’s stock valued at $9,474,000 after acquiring an additional 786,567 shares in the last quarter. BlackRock Inc. grew its holdings in shares of ADMA Biologics by 94.0% during the 2nd quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock valued at $7,343,000 after acquiring an additional 919,260 shares in the last quarter. Jefferies Group LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter valued at $2,961,000. Finally, Northern Trust Corp grew its holdings in shares of ADMA Biologics by 14.4% during the 2nd quarter. Northern Trust Corp now owns 299,248 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 37,677 shares in the last quarter. Hedge funds and other institutional investors own 59.10% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: Initial Public Offering (IPO)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.